Does high HER2 expression correlate with response to the combination of lapatinib and trastuzumab?
Increasing HER2 protein expression correlated with increased benefit of adding lapatinib to trastuzumab. HER2 expression is a stronger predictor of pCR and PFS than p95HER2 for response to lapatinib, trastuzumab and, more significantly, L+T.
The apparent association between structure and function in glaucoma, and consequent interpretation, varies with the statistical method and units of measure. Awareness of the limitations of any statistical analysis is necessary to avoid finding spurious results that ultimately may lead to inadequate clinical recommendations.